Blog Post
Corporate Venture Capital: Variations on a Theme (5 Key Terms)
30 November 2017
Kevin C. Clayton
PartnerWashington, D.C.
Email kevin.clayton@hoganlovells.com
Phone +1 202 637 5489
Fax +1 202 637 5910
Practice groupCorporate
Kevin Clayton is a practical and experienced adviser who brings a collaborative and cost-effective approach to corporate and commercial matters. He regularly advises clients on mergers and acquisitions, equity and debt financings, and complex contracting and corporate governance matters, particularly focusing on representation of funds, corporate investors, and emerging companies in financing, commercial, and acquisition transactions.
In addition to his two decades of advising on mergers and acquisitions and financing transactions, Kevin also has years of experience managing a wide array of commercial matters and complex contracting arrangements, such as license, supply, distribution, collaboration, manufacturing, service, employment, and consulting agreements.
While Kevin often represents emerging and growth-stage companies on formation, financing, commercial, and acquisition matters, he also advises later-stage and public companies, particularly with respect to acquisitions and licensing transactions.
Kevin represents clients in various industry sectors, but has particular experience with matters in the life sciences and technology sectors.
Education and admissions
Education
J.D., University of Virginia School of Law, 1998
B.A., University of Virginia, 1992
Bar admissions and qualifications
District of Columbia
Virginia
Representative experience
Represented Daimler AG in its investment in Via Transportation, Inc.
Represented New Enterprise Associates as lead investor in more than a dozen venture capital financing transactions over the past several years.
Represented OptiNose, Inc. in its US$37m Series D financing, prior equity and debt financings, and general corporate matters.
Represented Fred Hutchinson Cancer Research Center in Juno Therapeutics, Inc.'s formation and US$176m Series A financing, US$134m Series B financing, and related matters.
Represented PhishMe. Inc. in its US$42m Series C financing, prior equity and debt financings, general corporate matters, and its transaction with Malcovery Security, LLC.
Represented New York University in connection with Spin Transfer Technologies, Inc.'s US$70m financing and other similar transactions.
Represented publicly traded biotechnology company in several acquisitions and divestitures and numerous strategic venture investments.
Represented a luxury vacation club in a variety of equity financings, mortgage-backed debt financings, and acquisitions.
Represented Dental Care Alliance, LLC in its 2015 sale to Harvest Partners, LP.
